SUMMARY Six boys with ornithine carbamoyl transferase deficiency presenting in infancy or later childhood are described. There was wide variation in both the time of presentation and the symptoms, which may initially suggest a neurological, behavioural, or gastroenterological problem. Two patients died, as did two male siblings who were probably affected, but with early recognition of the hyperammonaemia the outlook is good.
Primary deficiency of ornithine carbamoyl transferase (EC 2.1.3.3) is the most common of the inherited disorders of the urea cycle. It has an X linked mode of inheritance and the hemizygous male usually develops severe hyperammonaemia in the neonatal period. The illness progresses rapidly with convulsions, coma, apnoea, and almost invariably death unless treated intensively.1
Although most of the affected males present in the neonatal period, a number have been reported who have presented later in infancy,' during childhood, or even in adult life. In some of these male patients the enzyme activity was reduced, which may explain the late onset,2 3 while in others the deficiency appeared to be complete despite the late presentation.
In this paper we describe six male patients with ornithine carbamoyl transferase deficiency who presented after the neonatal period. There was wide variation in the age of presentation and the symptoms. Certain aspects of two of the patients (cases 4 and 5) have been reported previously.6
Methods Enzyme activity was measured in biopsy specimens-liver or jejunal mucosa-by the method of Nuzum and Snodgrass with modifications,7 and urinary orotic acid by the method of Harris and Oberholzer.8 Rmol/l and the ornithine carbamoyl transferase activity of a specimen from needle biopsy taken immediately after death was reduced (table 2) . CASE 6 This boy was born after a normal pregnancy and delivery; he weighed 3200 g. There were no neonatal problems, but he did not feed well. He became ill for the first time at the age of 10 months when he was admitted to hospital with persistent vomiting and irritability. On examination there were no specific clinical signs. The only abnormal biochemical investigation was a slight rise in plasma aminotransferase activities. The ammonia concentration was not measured. Minor immunological abnormalities were detected and a diagnosis of food allergy made. One month after being admitted to the hospital he again became ill with episodes of lethargy, vomiting, irritability, and myoclonic jerks. His plasma ammonia concentration was raised (214 Rmol/l) with abnormal liver function. Urine orotic acid after a protein load was raised suggesting ornithine carbamoyl transferase deficiency, which was confirmed by enzyme studies (table 2) . A computed tomogram showed cerebral oedema. He was treated with a low protein diet, and has since done well on a normal diet with sodium benzoate.
Discussion
Ornithine carbamoyl transferase deficiency is X linked and most of the males are born with no detectable residual enzyme activity. They develop a severe illness in the neonatal period and unless intensively treated will die in the early months of life. Females have a much more variable presentation ranging from severe disease in infancy to those who remain asymptomatic. Males with mild disease have generally been considered to be rare and in a recent review only 18 cases were documented.' Ten further males have been described since then,915 and a number of others are incompletely reported. Most of the patients have presented in infancy with anorexia, vomiting, irritability, failure to thrive, and episodic encephalography. However, some patients have not presented until adult life.16 17 Sixteen out of the 28 patients died. We have described a further six patients with symptoms presenting as late as 12 years of age and it is likely that two other boys in these families, both of whom died, were also affected (siblings of cases 2 and 3 and 5).
The initial symptoms of hyperammonaemia are varied and may be subtle, including confusion, irritability, or behavioural problems. These may be misdiagnosed as psychiatric problems, drug abuse, and food allergy. Two patients complained of visual disturbances. Alternatively, the main symptom may be vomiting, particularly at times of metabolic stress such as infections so that a gastrointestinal disorder may be suspected. This presentation is common in infancy, combined with poor developmental progress. Routine biochemical investigation often shows raised plasma aminotransferase activities suggesting 'hepatitis'.
The mainstay of day to day treatment is a low protein diet, although patients with late onset ornithine carbamoyl transferase deficiency may need only modest protein restriction (1-5-2-2 g/kg/ day). Some will even be able to tolerate a normal diet. Other patients may prefer to eat a normal diet and to take sodium benzoate rather than be confined in what they eat. This compound is used to form an alternative pathway to urea for nitrogen excretion. 8 It is conjugated in the liver with glycine to form hippuric acid, which is rapidly excreted in the urine, thereby removing excess nitrogen. Given orally it is an effective and well tolerated drug for reducing plasma ammonia concentrations. The dose should not routinely exceed 250 mg/kg per day without monitoring plasma concentrations.19
Arginine is normally synthesised within the urea cycle and is not an essential amino acid. In ornithine carbamoyl transferase deficiency, however, because of the metabolic block it may become essential or semiessential in the more severely affected patients.
Some with the late onset forms of ornithine carbamoyl transferase deficiency may require additional arginine supplements during periods of rapid growth or when the plasma arginine concentrations are very low (less than 30 Rmol/l).19
Although the patients with late onset ornithine carbamoyl transferase deficiency may remain well for long periods, there is always a risk that hyperammonaemia may progress to more serious neurological problems such as coma and focal signs such as paraplegia and hemiplegia. Computed tomography may show focal hypodense areas.6 Once a child has reached this stage, unless the diagnosis is made rapidly and the correct treatment instituted, the outlook is poor. Nevertheless, with early and effective treatment with sodium benzoate, as in case 1, the outlook can be excellent. The usual dose in these circumstances is 250 mg/kg given over four hours and followed by the same dose in the next 20 hours.19
The factors that precipitate an attack are not always understood and there may be long intervals between hyperammonaemic episodes. Although infection is a common precipitating factor, not all infections cause problems, the response being unpredictable. It is particularly difficult to explain why the boy in case 5 did not develop severe hyperammonaemia in the neonatal period when he had a severe infection. Energy restriction was a contributing factor in the episodes of hyperammonaemia of case 1 accelerating protein catabolism and hence hyperammonaemia. 
